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1748 Abstracts June 2014EVAR and open repair. In the current study, the authors sought to analyze
the cost-effectiveness and cost-utility of EVAR compared with a standard
open repair in the treatment of rAAA, with costs per 30-day and 6-month
survival as outcome parameters. Resource use was determined from the
Amsterdam Acute Aneurysm trial data. Analysis was performed from a pro-
vider perspective. All costs were calculated as if patients had been treated in
the same teaching hospital (Onze Lieve Vrouwe Gasthuis). The study ran-
domized 116 patients. The 30-day mortality was 21% after EVAR and 25%
after open repair, for an absolute risk reduction of 4.4% (95% conﬁdence in-
terval [CI], 11.0% to 19.7%). At 6 months, the total mortality rate for
EVAR was 28% compared with 31% for those assigned to open repair (ab-
solute risk reduction, 2.4%; 95% CI, 14.2% to 19.0%). The mean cost dif-
ference between EVAR and OR was €5306 (95% CI, €1854 to €12,659) at
30 days and €10,189 (95% CI, e€2477 to €24,506) at 6 months. The incre-
mental cost-effectiveness ratio per prevented death was €120,591 at 30 days
and €424,542 at 6 months. There was no signiﬁcant difference in quality of
life between EVAR and OR. EVAR was not superior regarding cost-utility,
either. In this study, the mean costs of the EVAR group were substantially
raised by eight patients who required conversion to open repair. At 6
months, the mean difference between the converted and nonconverted
groups was €19,981. The total costs required to save one person’s life
with EVAR was €120,446. At 6 months, this leads to a number needed to
treat of 41.7 patients at €424,881 per life saved.
Comment: Overall, the Amsterdam Ruptured Aneurysm Study has
indicated that EVAR for treatment of rAAA is associated with a slightly
lower mortality rate but a considerably higher cost. The paper raises the
interesting point: At what point are advances in medical technology afford-
able, and at what point do they become cost-prohibitive?
Effect of the ﬁrst federally funded US antismoking national media
campaign
McAfee T, Davis KC, Alexander RL Jr, et al. Lancet 2013;382:2003-11.
Conclusions: A high-exposure media campaign can be effective in
increasing population-level quit attempts from smoking. The Tips media
campaign could have added from a third to almost half a million quality-
adjusted life-years to the United States (US) population.
Summary: Smoking kills >5 million people globally each year,
including 440,000 people in the US alone. The US Centers for Disease
Control and Prevention delivered a national, 3-month antismoking
campaign called Tips From Former Smokers (Tips) that started in March
2012, in which hard-hitting, emotionally evocative television advertising
was featured, depicting smoking-related suffering in real people. In this pa-
per, the authors access the effects of the Tips media campaign. The authors
performed baseline and follow-up surveys of nationally representative co-
horts of adult smokers and nonsmokers. The national effect of the Tips
campaign was estimated by applying rates of change in the cohort before
and after the campaign to US census data. In the study, 3051 smokers
and 2220 nonsmokers completed baseline and follow-up assessments. Of
these, 2395 smokers (78%) and 1632 nonsmokers (74%) recalled seeing
at least one Tips advertisement on television during the 3-month campaign.
Quit attempts among smokers rose from 31.1% (95% conﬁdence interval
[CI], 30.3%-31.9%) at baseline to 34.8% (95% CI, 34.0%-35.7%) at
follow-up, a 12% relative increase. The prevalence of abstinence at follow-
up among smokers who made a quit attempt was 13.4% (95% CI, 9.7%-
17.2%). Nationally, an estimated 1.64 million additional smokers made a
quit attempt, and 220,000 (95% CI, 159,000-282,000) remained abstinent
at follow-up. Recommendations by nonsmokers to quit grew from 2.6% at
baseline to 5.1% at follow-up, and the prevalence of people talking with
friends and family about the dangers of smoking rose from 31.9% (95%
CI, 31.3%-32.5%) to 35.2% (95% CI, 34.6%-35.9%), resulting in an esti-
mated 4.7 million additional nonsmokers recommending cessation services
and >6 million talking about the dangers of smoking.
Comment: The Tips media campaign was a $54 million initiative that
featured true emotional stories by former smokers to increase awareness of
the human suffering caused by smoking and to encourage quitting and moti-
vate nonsmokers to communicate with family and friends about the dangers
of smoking. The campaign started on March 19, 2012, and was completed
on June 10, 2012. Overall, enough Tips advertisements were broadcast for
about four of ﬁve smokers to see at least one message. About one-third of
television advertisements were tagged with 1-800-QUIT-NOW linking
viewers to their state telephone help line, and about two-thirds carried a
link to www.smokefree.gov, the National Cancer Institute’s quit assistance
Web site. The study demonstrates that immediate, measurable successful ef-
fects can be associated with a high-intensity public health campaign. Focused
antismoking media campaigns can be another weapon in the arsenal to end
the tobacco epidemic and potentially save millions of premature deaths and
decrease worldwide health care costs. Additional campaigns in the US and
internationally seem both medically and economically justiﬁed.Comparison of Pregabalin with Pramipexole for Restless Legs
Syndrome
Allen RP, Chen C, Garcia-Borreguero D, et al. N Engl J Med
2014;370:621-31.
Conclusions: Pregabalin signiﬁcantly improves treatment outcomes
of restless legs syndrome (RLS) compared with placebo, and augmentation
rates are signiﬁcantly lower with pregabalin than with 0.5 mg pramipexole.
Summary: RLS, also known as Willis-Ekbom disease, is a predomi-
nately nocturnal, rest-induced, distressing urge to move the legs. Anecdotally,
it seems to occur in a number of patients with peripheral vascular disease, and
clinically signiﬁcant RLS effects w2% to 3% of the European and American
populations (Allen RP et al, Sleep Med 2010;11:31-7). Short-acting dopa-
mine antagonists (pramipexole and ropinirole) and levodopa (Montplaisir J
et al, Neurology 1999;52:938-43 and Mov Disord 2006;21:1627-35) have
both been used for treatment. In this study, the authors sought to address
questions about the efﬁcacy of an alternative drug type in patients with
RLS and about the iatrogenic nature of RLS augmentation. This was a 1-
year blinded evaluation of efﬁcacy and augmentation. Comparison was
made between a dopaminergic drug pramipexole, administered at doses
approved by the Food and Drug Administration for the treatment of RLS,
with a nondopaminergic drug (pregabalin), an a2d ligand with analgesic
and anticonvulsant activity, also recently shown effective for treatment of
RLS. This was a randomized, double-blind trial. Patients were randomly
assigned to receive 52 weeks of treatment with pregabalin at a dose of
300 mg/d or pramipexole at a dose of 0.25 mg or 0.5 mg/d, or 12 weeks
of placebo followed by 40 weeks of randomly assigned active treatment.
The primary analyses involved a comparison of pregabalin and placebo over
a 12-week period with the use of the International RLS Study Group Rating
Scale, in which scores range from 0 to 40, with a higher score indicating more
severe symptoms. The Clinical Global Impression of Improvement scale was
also used to assess the proportion of patients with symptoms that were “very
much improved” or “much improved.” There was also comparison of RLS
augmentation with pregabalin and pramipexole over a period of 40 or
52 weeks of treatment. A total of 719 participants received daily treatment,
182 with 300 mg pregabalin, 178 with 0.25 mg pramipexole, 180 with
0.5 mg pramipexole, and 179 with placebo. Over 12 weeks, the improvement
(reduction) in mean scores on the International RLS scale was greater by 4.5
points among participants receiving pregabalin than among those receiving
placebo (P < .001), and the proportion of patients with symptoms that
were very much improved or much improved was also greater with pregabalin
than with placebo (71.4% vs 46.8%, P< .001). The rate of augmentation over
a period of 40 or 52 weeks was signiﬁcantly lower with pregabalin than with
pramipexole at a dose of 0.5 mg (2.1% vs 7.7%, P ¼ .001) but not at a dose of
0.25 mg (2.1% vs 5.3%, P ¼ .08). There were six cases of suicidal ideation in
the group receiving pregabalin, three in the group receiving 0.25 mg prami-
pexole, and two in the group receiving 0.5 mg pramipexole.
Comment: RLS is an irritating disorder affecting many elderly pa-
tients, including those with peripheral vascular disease. The authors’ data
suggest that pregabalin is an effective treatment for the disorder and that
worsening of the disorder can be due to an iatrogenic problem resulting
from dopaminergic medications. One would hope that the days of treat-
ment of RLS with a nocturnal dose of a mild sedative are over.
Prevalence of extracranial venous narrowing on catheter venography in
people with multiple sclerosis, their siblings, and unrelated healthy
controls: a blinded, case-control study
Traboulsee AL, Knox KB, Machan L, et al. Lancet 2014;383:138-45.
Conclusions: Chronic cerebrospinal venous insufﬁciency is rare in
both patients with multiple sclerosis and in healthy patients.
Summary: Multiple sclerosis affects >2 million people worldwide and
is a leading cause of neurologic disability. In recent years, a vascular origin of
multiple sclerosis has been proposed with the observation by Zamboni et al
that multiple stenoses of the extracranial venous drainage system may be pre-
sent in patients with multiple sclerosis. In the original paper, venous blockages
were present in all 65 patients with multiple sclerosis examined. This study
was with ultrasound and catheter venography (Zamboni P et al, J Neurol
Neurosurg Psychiatry 2009;80:392-9). These combinations of blockages
were not seen in healthy control participants who were studied by ultrasound
imaging or in patients with other diseases who underwent catheter venog-
raphy. It was therefore speculated that venous blockages have a central role
in the pathogenesis of multiple sclerosis and that treatment with venoplasty
may improve the course of the disease (Zamboni P et al, J Vasc Surg
2009;50:1348-58). Zamboni et al then performed an unblinded, uncon-
trolled interventional treatment using venoplasty in patients with multiple
sclerosis and claimed improvements in disability and quality of life. However,
independent research groups have not been able to reproduce the ﬁndings of
Zamboni et al regarding the diagnosis of chronic cerebrospinal venous
